Comparative Pharmacology
Head-to-head clinical analysis: ANDROID 10 versus FLUOXYMESTERONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANDROID 10 versus FLUOXYMESTERONE.
ANDROID 10 vs FLUOXYMESTERONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Androgen receptor agonist; testicular androgen responsible for development and maintenance of male sex characteristics and anabolic effects; increases protein synthesis and muscle mass.
Synthetic androgen receptor agonist; binds to androgen receptors, modulating gene expression and promoting protein synthesis, muscle growth, and secondary sexual characteristic development.
Testosterone undecanoate 750 mg (3 mL) intramuscular injection every 10 weeks, or testosterone cypionate 50-400 mg intramuscular injection every 2-4 weeks. For gel formulations: 50-100 mg transdermally once daily.
Adults: 5-20 mg orally once daily. For replacement therapy, 5-10 mg daily; for hypogonadism, 5-20 mg daily for several months.
None Documented
None Documented
Clinical Note
moderateAcarbose + Fluoxymesterone
"Acarbose may increase the hypoglycemic activities of Fluoxymesterone."
Clinical Note
moderateSunitinib + Fluoxymesterone
"Sunitinib may increase the hypoglycemic activities of Fluoxymesterone."
Clinical Note
moderatePrednisolone + Fluoxymesterone
"Prednisolone may increase the fluid retaining activities of Fluoxymesterone."
Clinical Note
moderateDexamethasone + Fluoxymesterone
8 hours; clinical context: steady-state achieved in 2-3 days, dosing interval 8-12 hours.
Terminal elimination half-life: 9.2 hours; clinical context: supports once-daily dosing for androgen replacement, with steady-state achieved in ~2 days
Renal: 90% as glucuronide and sulfate conjugates, 6% as unchanged drug; fecal: 4%.
Renal: 90% as glucuronide and sulfate conjugates; fecal: 10%
Category C
Category C
Androgen
Androgen
"Dexamethasone may increase the fluid retaining activities of Fluoxymesterone."